## Abstract LโAsparaginaseโinduced coagulation abnormalities were observed in all patients receiving this drug. All patients studied demonstrated low factor IX and fibrinogen levels and most (75%) had low levels of factor XI. Disturbances in other factors were much less frequent. Despite the presen
L-asparaginase reinduction and maintenance therapy in previously treated acute lymphocytic leukemia
โ Scribed by Sieger, Lance ;Higgins, Gussie ;Ortega, Jorge ;Shore, Nomie ;Williams, Kenneth
- Publisher
- John Wiley and Sons
- Year
- 1976
- Tongue
- English
- Weight
- 371 KB
- Volume
- 2
- Category
- Article
- ISSN
- 0098-1532
No coin nor oath required. For personal study only.
โฆ Synopsis
Abstract
Four patients with acute lymphocytic leukemia previously treated with conventional chemotherapy received intramuscular Lโasparaginase in combination with other chemotherapy for reinduction and maintenance therapy. These patients received the Lโasparaginase for 8, 14, 27, and 34+ months without demonstrating any significant adverse effects. Only 1 of the 4 was clearly resistant to the other chemotherapy, and 3 of 4 had recurrence of their disease while receiving Lโasparaginase. Lโasparaginase can be added to reinduction and maintenance regimens of patients resistant to other chemotherapy and is well tolerated for long periods when given intramuscularly weekly with other immunosuppressant agents.
๐ SIMILAR VOLUMES
A remission-induction regimen for childhood leukemia using cyclophosphamide, asparaginase, vincristine, and prednisone (CAVP) was compared to standard vincristine-prednisone (VP) induction. The more intensive regimen was associated with a lower complete remission rate (81% vs 93%) and a higher early
A study of children in relapse with acute nonlymphocytic leukemia (ANLL) previously maintained in remission with combination chemotherapy including cytosine arabinoside (Ara-C) was undertaken by Children's Cancer Study Group (CCSG) to assess the efficacy of cyclocytidine (Cyclo-C), a depot Ara-C, co